Viking Global Investors — BBIO Trade History

Quarter-by-quarter changes in the BRIDGEBIO PHARMA INC position · CUSIP 10806X102
Currently held · 7.3 YearsFirst seen: 2019 Q2
QuarterFiledActivitySharesΔ SharesΔ %Value% Port.
2026 Q22026-08-14Reduce9,949,219-1,893,215-16.0%$741.0M2.11%
2026 Q12026-05-15Reduce11,842,434-2,551,500-17.7%$879.4M2.46%
2025 Q42026-02-17Reduce14,393,934-1,583,915-9.9%$1.10B2.92%
2025 Q32025-11-14Reduce15,977,849-2,577,526-13.9%$829.9M2.15%
2025 Q22025-08-14Reduce18,555,375-3,500,000-15.9%$801.2M2.32%
2025 Q12025-05-15Reduce22,055,375-3,065,616-12.2%$762.5M2.42%
2024 Q42025-02-14Hold25,120,9910.0%$689.3M2.23%
2024 Q32024-11-14Hold25,120,9910.0%$639.6M2.33%
2024 Q22024-08-14Hold25,120,9910.0%$636.3M2.44%
2024 Q12024-05-15Hold25,120,9910.0%$776.7M2.89%
2023 Q42024-02-14Hold25,120,9910.0%$1.01B3.71%
2023 Q32023-11-14Reduce25,120,991-1,500,000-5.6%$662.4M2.69%
2023 Q22023-08-14Hold26,620,9910.0%$457.9M1.88%
2023 Q12023-05-15Hold26,620,9910.0%$441.4M2.07%
2022 Q42023-02-14Hold26,620,9910.0%$202.9M1.01%
2022 Q32022-11-14Hold26,620,9910.0%$264.6M1.22%
2022 Q22022-08-15Hold26,620,9910.0%$241.7M1.11%
2021 Q32022-05-16Hold26,620,9910.0%$1.25B3.42%
2021 Q42022-05-16Hold26,620,9910.0%$444.0M1.28%
2022 Q12022-05-16Hold26,620,9910.0%$270.2M1.09%
2021 Q22021-08-16Hold26,620,9910.0%$1.62B4.92%
2021 Q12021-05-17Hold26,620,9910.0%$1.64B4.88%
2020 Q42021-02-16Hold26,620,9910.0%$1.89B5.21%
2020 Q32020-11-16Hold26,620,9910.0%$998.8M3.61%
2020 Q22020-08-07Hold26,620,9910.0%$868.1M3.75%
2020 Q12020-05-13Hold26,620,9910.0%$772.0M4.02%
2019 Q42020-02-13Hold26,620,9910.0%$933.1M4.37%
2019 Q32019-11-13Hold26,620,9910.0%$571.6M2.98%
2019 Q22019-08-14New26,620,99126,620,991$718.0M3.22%
2019 Q12019-05-15
2018 Q42019-02-14
2018 Q32018-11-14
2018 Q22018-08-14
2018 Q12018-05-15
2017 Q42018-02-14
2017 Q32017-11-14
2017 Q22017-08-14
2017 Q12017-05-15
2016 Q42017-02-14
2016 Q32016-11-14

Share counts are split-adjusted. Time held counts consecutive quarters ending with the latest filing; more than ten years shows as ">10 Years".

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.